519 related articles for article (PubMed ID: 12682003)
1. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
[TBL] [Abstract][Full Text] [Related]
2. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
[TBL] [Abstract][Full Text] [Related]
5. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
[TBL] [Abstract][Full Text] [Related]
6. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
Piccolo R; Eitel I; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
EuroIntervention; 2014 Jan; 9(9):1110-20. PubMed ID: 24457282
[TBL] [Abstract][Full Text] [Related]
7. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI.
Romagnoli E; Burzotta F; Trani C; Mazzari MA; Biondi-Zoccai GG; De Vita M; Giannico F; Niccoli G; Prati F; Rebuzzi AG; Mongiardo R; Crea F
Int J Cardiol; 2005 Dec; 105(3):250-5. PubMed ID: 16274764
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Lansky AJ; Pietras C; Costa RA; Tsuchiya Y; Brodie BR; Cox DA; Aymong ED; Stuckey TD; Garcia E; Tcheng JE; Mehran R; Negoita M; Fahy M; Cristea E; Turco M; Leon MB; Grines CL; Stone GW
Circulation; 2005 Apr; 111(13):1611-8. PubMed ID: 15811868
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
[TBL] [Abstract][Full Text] [Related]
10. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
Eitel I; Wöhrle J; Suenkel H; Meissner J; Kerber S; Lauer B; Pauschinger M; Birkemeyer R; Axthelm C; Zimmermann R; Neuhaus P; Brosteanu O; de Waha S; Desch S; Gutberlet M; Schuler G; Thiele H
J Am Coll Cardiol; 2013 Apr; 61(13):1447-54. PubMed ID: 23466078
[TBL] [Abstract][Full Text] [Related]
11. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
[TBL] [Abstract][Full Text] [Related]
14. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
[TBL] [Abstract][Full Text] [Related]
15. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A; Abildgaard U; Galloe A; Hansen PR; Galatius S; Madsen JK; Engstroem T; Pedersen S; Jensen KS; Jensen JS
J Interv Cardiol; 2011 Apr; 24(2):105-11. PubMed ID: 21175845
[TBL] [Abstract][Full Text] [Related]
16. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
De Luca G; Verdoia M; Suryapranata H
Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
[TBL] [Abstract][Full Text] [Related]
17. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
[TBL] [Abstract][Full Text] [Related]
18. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
19. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
[TBL] [Abstract][Full Text] [Related]
20. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
Gunasekara AP; Walters DL; Aroney CN
Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
